NEW YORK (GenomeWeb) – Belgian cancer theranostics firm OncoDNA today announced an exclusive distribution deal granting Greek anatomic pathology laboratory Istomedica the exclusive rights to OncoDNA's products in Greece.

OncoDNA will be Istomedica's preferred supplier of clinical grade molecular theranostics using OncoDeep Dx, which links specific genes to targeted cancer treatments, and clinical cancer panels, in combination with Package Plus, a set of cancer tests based on immunohistochemical, fluorescent in situ hybridization, methylation, and other technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.